Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioShield Should Extend Liability Protection To Unapproved Products – BIO

Executive Summary

Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said

You may also be interested in...



“BioShield” Law Nears Passage; FDA Proposes “Pre-Pre-IND” Meetings

FDA counterterrorism regulations will likely face added scrutiny following the expected enactment of Project BioShield, which allows for wider use of investigational products in emergency situations

“BioShield” Law Nears Passage; FDA Proposes “Pre-Pre-IND” Meetings

FDA counterterrorism regulations will likely face added scrutiny following the expected enactment of Project BioShield, which allows for wider use of investigational products in emergency situations

BioShield House Compromise Could Serve As Template For Senate

The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel